Skip to Content
Merck
All Photos(2)

Documents

RAB0484

Sigma-Aldrich

Human Osteoprotegerin / TNFRSF11b ELISA Kit

for serum, plasma, cell culture supernatant and urine

Synonym(s):

OPG

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
41116158
NACRES:
NA.32

species reactivity

human

packaging

kit of 96 wells (12 strips x 8 wells)

technique(s)

ELISA: suitable
capture ELISA: suitable

input

sample type serum
sample type urine
sample type cell culture supernatant(s)
sample type plasma

assay range

inter-assay cv: <12%
intra-assay cv: <10%
sensitivity: 1 pg/mL
standard curve range: 1.23-900 pg/mL

detection method

colorimetric

shipped in

wet ice

storage temp.

−20°C

Gene Information

General description

The Human Osteoprotegerin ELISA (Enzyme-Linked Immunosorbent Assay) kit is an in vitro enzyme-linked immunosorbent assay for the quantitative measurement of human Osteoprotegerin in serum, plasma, cell culture supernatants and urine.

Osteoprotegerin (OPG) is encoded by the gene mapped to human chromosome 8q24. It is a member of the TNFR (tumor necrosis factor receptor) superfamily that can act as a decoy receptor for RANKL (receptor activator of nuclear factor kappa-B ligand) and TRAIL (tumor necrosis factor-related apoptosis-inducing ligand). OPG is expressed in a wide variety of tissues, including adult heart, lung, kidney and liver. It is secreted both as a monomeric and a dimeric protein.

Immunogen

Recombinant Human OPG

Application

For research use only. Not for use in diagnostic procedures.
Please refer to the attached General ELISA KIT Procedure (sandwich, competitive & Indirect ELISA)

Biochem/physiol Actions

Binding of soluble osteoprotegerin (OPG) to sRANKL (soluble receptor activator of nuclear factor κ-B ligand) inhibits osteoclastogenesis by interrupting the signaling between stromal cells and osteoclastic progenitor cells. This process leads to excess accumulation of bone and cartilage. Changes in the level of serum OPG are associated with atherosclerosis and cardiovascular disorders(CVDs). It might also be associated with malignancy and plays a regulatory role in multiple myeloma, prostate, breast, bladder and gastric carcinoma. OPG plays a vital role in bone metabolism and is involved in inhibition of ovariectomy-associated bone loss in rats. It is also used as a potent biomarker for CVD.

Other Notes

A sample Certificate of Analysis is available for this product.
Please type the word sample in the text box provided for lot number.

Kit Components Also Available Separately

Product No.
Description
SDS

  • RABELADAELISA 1X Assay/Sample Diluent Buffer A (Item D1)SDS

  • RABELADBELISA 5X Assay/Sample Diluent Buffer B (Item E1)SDS

  • RABSTOP3ELISA Stop Solution (Item I)SDS

  • RABTMB3ELISA Colorimetric TMB Reagent (HRP Substrate, Item H)SDS

  • RABWASH420X Wash Buffer (Item B)SDS

Pictograms

Corrosion

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Met. Corr. 1

Storage Class Code

8A - Combustible corrosive hazardous materials


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis.
Goswami S and Neelam S-W
BMC Cancer, 15(1), 935-935 (2015)
Allison P Garcia et al.
Journal of clinical pharmacology, 60(2), 209-217 (2019-09-20)
This pilot study examined how exemestane (an aromatase inhibitor [AI]) affected osteoprotegerin (OPG) urine concentrations in postmenopausal women. Exemestane (25 mg, single dose) was given to 14 disease-free women past menopause in this nonrandomized, open-label study. Before dosing, urine specimens
Roles and clinical applications of OPG and TRAIL as biomarkers in cardiovascular disease.
Bernardi S, et al.
BioMed Research International, 2016, 12-12 (2016)
Functions of RANKL/RANK/OPG in bone modeling and remodeling.
Boyce BF and Xing L.
Archives of Biochemistry and Biophysics, 473(2), 139-146 (2008)
Osteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet WS
Cell, 89(2), 309-319 (1997)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service